700 related articles for article (PubMed ID: 36949949)
21. Synthetic T cell receptor-based lymphocytes for cancer therapy.
Getts D; Hofmeister R; Quintás-Cardama A
Adv Drug Deliv Rev; 2019 Feb; 141():47-54. PubMed ID: 30981835
[TBL] [Abstract][Full Text] [Related]
22. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.
Pinte L; Cunningham A; Trébéden-Negre H; Nikiforow S; Ritz J
Front Immunol; 2020; 11():608485. PubMed ID: 33658994
[TBL] [Abstract][Full Text] [Related]
23. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
25. Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4.
Alsalloum A; Shevchenko J; Fisher M; Philippova J; Perik-Zavodskii R; Perik-Zavodskaia O; Alrhmoun S; Lopatnikova J; Vasily K; Volynets M; Zavjalov E; Solovjeva O; Akahori Y; Shiku H; Silkov A; Sennikov S
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894816
[TBL] [Abstract][Full Text] [Related]
26. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cells therapy in solid tumors.
Rababah F; Alabduh T; Awawdeh A; Shatnawi T; Al-Shdaifat M; Ibdah E; Shatnawi S; AbuZetun Y; Helaly AM; Ghorab DS
Clin Transl Oncol; 2023 Aug; 25(8):2279-2296. PubMed ID: 36853399
[TBL] [Abstract][Full Text] [Related]
28. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
29. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
30. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
32. Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance.
Füchsl F; Krackhardt AM
Cells; 2022 Jan; 11(3):. PubMed ID: 35159220
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
34. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
35. Clinical Investigations of CAR-T Cell Therapy for Solid Tumors.
Chen K; Wang S; Qi D; Ma P; Fang Y; Jiang N; Wu E; Li N
Front Immunol; 2022; 13():896685. PubMed ID: 35924243
[TBL] [Abstract][Full Text] [Related]
36. Current challenges and emerging opportunities of CAR-T cell therapies.
Abreu TR; Fonseca NA; Gonçalves N; Moreira JN
J Control Release; 2020 Mar; 319():246-261. PubMed ID: 31899268
[TBL] [Abstract][Full Text] [Related]
37. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
38. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
[TBL] [Abstract][Full Text] [Related]
39. Exploiting T cell signaling to optimize engineered T cell therapies.
Wang H; Song X; Shen L; Wang X; Xu C
Trends Cancer; 2022 Feb; 8(2):123-134. PubMed ID: 34810156
[TBL] [Abstract][Full Text] [Related]
40. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
